A Model for Drug Concentration Prediction of Vancomycin
Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · May 27, 2024
Trial Information
Current as of February 19, 2025
Active, not recruiting
Keywords
ClinConnect Summary
Background: Vancomycin is a glycopeptide antibiotic primarily used to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA). As a time-dependent antibiotic, the serum concentration of vancomycin is closely related to the clinical efficacy, toxicity and emergence of drug resistance. Therefore, therapeutic drug monitoring (TDM) is considered an important component of vancomycin treatment management. According to vancomycin surveillance guidelines, It is recommended to maintain a serum vancomycin concentration of 15-20 mg/L in patients with severe infections in order to...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years;
- • Patients admitted to ICUs;
- • Patients were administered intravenous vancomycin;
- • Vancomycin TDM was performed at least two times.
- Exclusion Criteria:
- • Vancomycin TDM was performed in a ward rather than in an ICU;
- • Patients with missing data.
Trial Officials
Li Weng, MD
Study Chair
Peking Union Medical College Hospital
About Peking Union Medical College Hospital
Peking Union Medical College Hospital (PUMCH) is a prestigious medical institution and a leading research facility located in Beijing, China. Affiliated with the Chinese Academy of Medical Sciences, PUMCH is renowned for its commitment to advancing healthcare through innovative clinical research and high-quality patient care. The hospital plays a pivotal role in the development and execution of clinical trials across various medical disciplines, focusing on improving treatment outcomes and enhancing medical knowledge. With a multidisciplinary team of experts and state-of-the-art facilities, PUMCH is dedicated to contributing to global health advancements and fostering collaborations in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0